Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/24845
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Potential Benefits of Sequential Inhibitor-Mutagen Treatments of RNA Virus Infections |
Autor: | Perales, Celia CSIC ORCID; Agudo, Rubén CSIC ORCID; Tejero, Héctor; Manrubia Cuevas, Susanna CSIC ORCID ; Domingo, Esteban CSIC ORCID | Palabras clave: | Foot-and-mouth disease virus (FMDV) Antiviral inhibitor guanidine (GU) |
Fecha de publicación: | 13-nov-2009 | Editor: | Public Library of Science | Citación: | PLoS Pathogens 5(11): e1000658 | Resumen: | Lethal mutagenesis is an antiviral strategy consisting of virus extinction associated with enhanced mutagenesis. The use of non-mutagenic antiviral inhibitors has faced the problem of selection of inhibitor-resistant virus mutants. Quasispecies dynamics predicts, and clinical results have confirmed, that combination therapy has an advantage over monotherapy to delay or prevent selection of inhibitor-escape mutants. Using ribavirin-mediated mutagenesis of foot-and-mouth disease virus (FMDV), here we show that, contrary to expectations, sequential administration of the antiviral inhibitor guanidine (GU) first, followed by ribavirin, is more effective than combination therapy with the two drugs, or than either drug used individually. Coelectroporation experiments suggest that limited inhibition of replication of interfering mutants by GU may contribute to the benefits of the sequential treatment. In lethal mutagenesis, a sequential inhibitor-mutagen treatment can be more effective than the corresponding combination treatment to drive a virus towards extinction. Such an advantage is also supported by a theoretical model for the evolution of a viral population under the action of increased mutagenesis in the presence of an inhibitor of viral replication. The model suggests that benefits of the sequential treatment are due to the involvement of a mutagenic agent, and to competition for susceptible cells exerted by the mutant spectrum. The results may impact lethal mutagenesis-based protocols, as well as current antiviral therapies involving ribavirin. | Versión del editor: | http://dx.doi.org/10.1371/journal.ppat.1000658 | URI: | http://hdl.handle.net/10261/24845 | DOI: | 10.1371/journal.ppat.1000658 | ISSN: | 1553-7366 |
Aparece en las colecciones: | (CBM) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
EDomingo_PlosPath_1000658.pdf | 624,99 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
40
checked on 06-may-2024
SCOPUSTM
Citations
61
checked on 06-may-2024
WEB OF SCIENCETM
Citations
59
checked on 25-feb-2024
Page view(s)
325
checked on 07-may-2024
Download(s)
222
checked on 07-may-2024
Google ScholarTM
Check
Altmetric
Altmetric
Artículos relacionados:
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.